0
Home
News
Directory
E-newsletter
Magazine
Events
Data
AgReport
Subscribe
Revolutionary DowDuPont technology available for the first time worldwide to accelerate discovery of novel protein drugs
Mar. 19, 2018
DowDuPont
United StatesFollow
United States
Proteins are the building blocks of science and the speed, quality and efficiency of protein production research is being advanced through an agreement between Dow AgroSciences LLC, and life sciences startup LenioBio. The companies announced an exclusive license to enable LenioBio to utilize Dow AgroSciences' proprietary eukaryotic cell-free protein expression technology. LenioBio will market the innovation to biopharmaceutical developers under the brand name ALiCE ™.
While cell-free protein expression done today enables protein chemists to quickly produce small amounts of proteins when screening DNA libraries, there is a need for higher protein expression yields. The higher production efficiencies gained by ALiCE™ will make it possible for biopharmaceutical researchers to detect a significantly higher number of candidates from each DNA library screened, eventually leading to a higher number of viable candidates for development. ALiCE™ also offers the option to produce larger quantities of proteins.
This innovative cell-free protein expression system was developed by Dow AgroSciences in collaboration with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME under a long-standing strategic alliance. This technology has been used successfully in agricultural research.
"Today's protein research demands speed and robust technology. Our cell-free approach enables high-quantity protein to be produced and validated in days instead of weeks. Dow AgroSciences, together with our partner Fraunhofer IME, are committed to making the technology accessible to the biopharmaceutical market, and this license to LenioBio is key to the development and commercialization of this technology," said Steven Webb, Ph.D., External Technology Leader, Dow AgroSciences.
"ALiCE™ is superior in terms of protein yield to other cell-free expression systems currently on the market, which makes it ideal for the discovery of new protein drugs. We want to enable biopharmaceutical developers and other protein chemists to take full advantage of this system, which has established a solid record of accomplishment with Dow AgroSciences," said Remberto Martis, Ph.D., Co-founder and Chief Executive Officer of LenioBio.
LenioBio will launch the ALiCE™ platform this year initially as an expression kit that yields much higher amounts of proteins on average than other cell-free protein expression kits. Going forward, the company also will launch a unique protein production toolbox for biopharmaceutical developers to fine-tune and produce their protein candidates for pre-clinical and clinical trials in-house.
Source: DowDuPont press release
More from AgroNews
Change
Hot TopicSubscribe
| Subscribe Email: | * | |
| Name: | ||
| Mobile Number: | ||
Comment
0/1200
NEWSLETTER